Supplementation of standard treatment with high-dose levothyroxine (L-T 4 ) is a novel approach for treatment-refractory bipolar disorders. This study tested for effects on brain function associated with mood alterations in bipolar depressed patients receiving high-dose L-T 4 treatment adjunctive to ongoing medication (antidepressants and mood stabilizers). Regional activity and whole-brain analyses were assessed with positron emission tomography and [ 18 F]fluorodeoxyglucose in 10 euthyroid depressed women with bipolar disorder, before and after 7 weeks of open-label adjunctive treatment with supraphysiological doses of L-T 4 (mean dose 320 lg/day). Corresponding measurements were acquired in an age-matched comparison group of 10 healthy women without L-T 4 treatment. The primary biological measures were relative regional activity (with relative brain radioactivity taken as a surrogate index of glucose metabolism) in preselected brain regions and neuroendocrine markers of thyroid function. Treatment-associated changes in regional activity (relative to global activity) were tested against clinical response. Before L-T 4 treatment, the patients exhibited significantly higher activity in the right subgenual cingulate cortex, left thalamus, medial temporal lobe (right amygdala, right hippocampus), right ventral striatum, and cerebellar vermis; and had lower relative activity in the middle frontal gyri bilaterally. Significant behavioral and cerebral metabolic effects accompanied changes in thyroid hormone status. L-T 4 improved mood (remission in seven patients; partial response in three); and decreased relative activity in the right subgenual cingulate cortex, left thalamus, right amygdala, right hippocampus, right dorsal and ventral striatum, and cerebellar vermis. The decrease in relative activity of the left thalamus, left amygdala, left hippocampus, and left ventral striatum was significantly correlated with reduction in depression scores. Results of the whole-brain analyses were generally consistent with the volume of interest results. We conclude that bipolar depressed patients have abnormal function in prefrontal and limbic brain areas. L-T 4 may improve mood by affecting circuits involving these areas, which have been previously implicated in affective disorders. Molecular Psychiatry (2005) 10, 456-469.
Many patients with bipolar disorder do not respond adequately to standard medications, and require a novel treatment strategy. 1, 2 In this regard, adjunctive use of levothyroxine (L-T 4 ) at supraphysiological doses offers promise for patients who suffer rapid cycling [3] [4] [5] [6] and prophylaxis-resistant bipolar disorders, [6] [7] [8] [9] for patients with bipolar and unipolar disorder during a phase of refractory major depressive episode, 10 and patients with refractory chronic depression and dysthymia. 11 Despite knowledge of the role of thyroid hormones in the maturation and the differentiation of the brain, 12, 13 and the association between thyroid status and behavioral disturbances in thyroid disease, 14, 15 the action of thyroid hormones in the adult brain has received comparatively little attention. This disinterest followed reports in the 1950s and 1960s, suggesting that oxygen consumption in the mature human brain did not change with thyroid status. [16] [17] [18] Recent studies of the mature mammalian brain have begun to change this situation, 13, [19] [20] [21] [22] [23] with new evidence suggesting that thyroid hormones are critically important in maintaining the optimal level of metabolic activity in the mature brain. 20, [24] [25] [26] For example, hypothyroid adult rats exhibit deficits in 2-deoxy-D [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]glucose uptake by most brain regions, indicating a general cerebral metabolic deficiency. 27 In addition, serum TSH (inversely related to thyroid hormone levels) is inversely related to cerebral metabolism and blood flow in the dorsolateral and mesial prefrontal cortices of human euthyroid patients with major depression. 28 Most neuroimaging studies of affective disorder, however, have not considered thyroid status, and have focused primarily on unipolar major depressive disorder (MDD). [29] [30] [31] [32] Most of the findings in positron emission tomographic (PET) studies indicated lower metabolic activity in the dorsomedial and dorsolateral prefrontal cortices (DLPFC) and higher activity in the ventrolateral prefrontal cortex (VLPFC) of individuals with MDD when compared to activities in healthy control subjects. [30] [31] [32] Fewer investigations focused on the depressive phase of bipolar disease. 33 PET studies that compared individuals with bipolar depression to controls also found abnormal relative glucose metabolism in prefrontal cortical as well as subcortical brain areas. In unmedicated bipolar depressed patients, resting with their eyes closed, Drevets et al 34 observed lower relative glucose metabolism in a small region of the cingulate gyrus ventral to the genu of the corpus callosum, which they described as subgenual prefrontal cortex. Baxter et al 35 observed lower glucose metabolism in the DLPFC as well as higher glucose metabolism in the basal ganglia and thalamus of bipolar depressed patients. In the largest study of treatment-resistant bipolar depression, Ketter et al 36 also found lower prefrontal cortical activity and higher subcortical activity (bilateral thalamus, ventral striatum, cerebellum, and right amygdala) compared with healthy control subjects. Studies of patients with bipolar disorder generally indicated that the abnormalities observed during the depressed phase were attenuated during euthymic intervals. 30, 33 Recent functional magnetic resonance imaging (fMRI) studies reported less DLPFC activation and more amygdalar activation in adults with bipolar depression than in control subjects viewing fearful faces; 37 another fMRI study showed more ventral prefrontal cortex activation during an event-related color-naming Stroop interference task. 38 This report extends earlier studies of affective disorder and explores the effects of adjunctive supraphysiological doses of L-T 4 on regional brain function in women with bipolar depression. Only women were studied here because previous work has indicated that women benefit more than do men from thyroid hormone supplementation. [39] [40] On the basis of previous findings from functional PET studies in bipolar depression, we hypothesized that patients with bipolar depression would have lower relative activity in the middle frontal gyri (within the DLPFC) 35 and the region described by Drevets et al 34 as subgenual prefrontal cortex (here renamed more descriptively as the subgenual cingulate cortex), and higher activity in subcortical and limbic structures 36 compared to healthy controls. We further hypothesized that adjunctive L-T 4 treatment would improve mood in bipolar depressed patients, and that clinical improvement would be associated with increased activity in the prefrontal cortex and decreased activity in limbic and subcortical structures, including the basal ganglia and thalamus.
Materials and methods

Study design
This prospective, open-label, 7-week study was approved by the UCLA institutional review board. It tested the efficacy of adjunctive treatment with supraphysiological doses of L-T 4 in women with bipolar depression who were unresponsive to an antidepressant trial (see below), and studied the relation of clinical response to possible alterations in regional brain function. Two groups (bipolar depressed and healthy control) were tested with measures of mood and brain function at two time points. For the bipolar group, the times were before and after the course of L-T 4 treatment. The control group was tested at corresponding times to provide a measure of order effects, but was not treated with thyroid hormone. The measure of brain function used was normalized decay-corrected raw counts (from the radiotracer [F-18] fluorodeoxyglucose, FDG) as a surrogate index of glucose metabolism. Relative activity, as used in this report, refers to this measure.
Subjects
All of the research participants were recruited over 1 year, through flyers that described the study. Flyers were given to each female patient with bipolar depression, admitted to the UCLA Mood Disorders Clinic, and also were posted at the UCLA Medical Center. Following a prescreening interview, the first 14 consecutive potential subjects who provided evidence of meeting the entry study criteria, including bipolar depression that was unresponsive to at least 6 weeks of antidepressant treatment, were invited to participate. Four of these 14 bipolar subjects were excluded from further participation due to the results of the screening procedures. Of the remaining 10 subjects (all right handed), nine were diagnosed with bipolar I disorder, and one with bipolar II disorder. All of the potential volunteers who maintained interest in the study (n ¼ 10) were enrolled. After providing written informed consent, participants received a psychiatric interview supplemented by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) 41 to confirm the diagnosis of bipolar disorder, depressed phase, a complete medical and physical examination, a routine laboratory evaluation (thyroid function tests, blood count, blood chemistry, urine drug screen), vital signs, and a 12-lead electrocardiogram (ECG). Affective symptoms were assessed with the clinician-rated 21-item Hamilton Rating Scale for Depression (HRSD 21 ), 42 the self-rated Beck Depression Inventory (BDI), 43 and the Clinical Global Impression for Bipolar Disorder scale (CGI-BP, Severity and Change from Worst Week within this Episode) 44 on each day that a PET scan was acquired. An experienced research assistant, who did not participate in treatment and was not informed about the purpose of the study, performed the clinical ratings.
Patients who were invited to continue into the treatment phase of the study were between 18 and 55 years of age, and had the diagnosis of bipolar I or II disorder with a depressive episode (DSM-IV) and a score of Z15 on the HRSD 21 despite antidepressant therapy (Z6 weeks, standard doses of at least one antidepressant) (see below) . They had received the same antidepressant during the 6 weeks before study entry, with no changes in dose during the 3 weeks before entry. They also were euthyroid (serum TSH 0.3-4.7 mIU/ml). Exclusionary criteria for further participation were: (1) psychotic features or history of schizoaffective disorder/schizophrenia; (2) organic brain disorder; (3) thyroid adenoma and hyperthyroid conditions; (4) unstable medical illnesses; (5) endocrine disorders; (6) severe cardiovascular diseases; (7) intake of thyroid hormones during the 4 months prior to study entry; (8) clinical judgement that the subject presented a serious suicidal risk.
Control subjects were recruited through flyers and advertisements in the UCLA campus newspaper. They were in good general health and underwent the same psychiatric screening procedures as described above for bipolar subjects. The inclusion criteria were: (1) age between 18 and 55 years, (2) no current or past mental disorder on the basis of a SCID I interview and a negative history of major organic brain disease, (3) score of 3 or less on the HRSD 21 throughout the study, (4) no intake of any hormonal agents or psychotropic agents for at least 4 months prior to study, (5) no history of endocrine, cardiac, or other severe medical disease, and (6) no family member with a major affective disorder.
Pregnancy or lactation, childbirth within the year before volunteering for the study, and childbearing potential without the use of contraception were exclusionary criteria for both groups. Current dependence on an addictive substance or remarkable substance abuse with a positive urine test were also exclusionary.
Procedures
At weekly visits, a clinical evaluation and adverse event assessment were performed; and body weight and vital signs were assessed. Cardiac (including ECG) and thyroid function tests were performed every second week. Untoward events were assessed from spontaneous self-reports. In addition, the clinician asked the subject if any events independent of any causal relationship had come to attention, using the Thyroid Symptom List. 7, 45 The dose of L-T 4 (Levothroid s ) was administered once daily (30 min before breakfast) in addition to the antidepressant and mood stabilizer medication that the patients were receiving but to which they were not responding. The L-T 4 dose was 100 mg/day for the first week, 200 mg/day for the second week and 300 mg/ day for week 3-7; if TSH was not suppressed by the end of week 3, the L-T 4 dose was increased to 400 mg/ day. At study entry, patients were receiving the following psychotropic medications: citalopram, n ¼ 1 (20 mg/day); bupropion, n ¼ 2 (300 and 400 mg/ day); fluoxetine, n ¼ 2 (20 mg/day); paroxetine, n ¼ 1 (20 mg/day); sertraline, n ¼ 1 (150 mg/day)); trazodone, n ¼ 1 (150 mg/day); venlafaxine, n ¼ 3 (150-375 mg/day); divalproex sodium, n ¼ 4 (500-1500 mg/ day); gabapentin, n ¼ 1 (900 mg/day); lamotrigine, n ¼ 1 (300 mg/day); lithium carbonate, n ¼ 4 (300-1200 mg/day); topiramate, n ¼ 2 (75 and 200 mg/day, respectively). There was no change in treatment with any of these medications throughout the study. The mean duration of the current episode of depression at the time of entry to the study was 1717125 days.
None of the research participants received hormone replacement therapy. All bipolar and control subjects were premenopausal (evidenced by urine ovulation test) except for one patient with bipolar disorder (aged 53 years) with unknown menopause status due to past hysterectomy.
Clinical outcome measures
The primary clinical efficacy measure was the HRSD 21 (analyzed by end point method). Secondary efficacy measures were the BDI and CGI-BP, and included remission rates; full response (remission) was defined as a Z50% reduction in the HRSD 21 score and a final score of r7; partial response was defined as Z50% decrease in the HRSD 21 score and a final score of Z8.
Magnetic resonance imaging
Structural magnetic resonance imaging (MRI) scans (3-T, General Electric) included T1 volumetric scans (spoiled-gradient-recalled acquisition, 256 Â 256 matrix, TE ¼ 4 msec, TR ¼ 24 msec, angle ¼ 351, 1.22-mm. slice thickness) and were used for coregistration with PET data. T2 (spin echo) scans (256 Â 256 matrix, TE 34 msec, TR 5500 s, 1 NEX, 2-mm slice thickness) from all subjects included were read as clinically normal.
PET imaging
Each subject participated in two PET scanning sessions with FDG to assess relative activity. 46, 47 Those with bipolar disorder received the first PET scan before L-T 4 treatment and the second after 7 weeks of treatment. There was no statistically significant group difference in the interval between the first and the second PET evaluation (P ¼ 0.72). Thyroid status and psychiatric ratings were assessed on the morning of each PET scan.
Before the PET measurement, a catheter was inserted into the antecubital vein for infusing FDG. Beginning before injection of the FDG and continuing during the uptake period, the subject performed an auditory continuous performance task (CPT), which we administered in order to provide a consistent cognitive set for all of the subjects. The CPT required discrimination of a target tone (higher pitch), presented within a sequence (inter-stimulus interval ¼ 2 s) of distracting tones (lower pitch). The subject pressed a button to signify hearing a target tone.
PET images were acquired with a Siemens ECAT EXACT HR þ tomograph (CTI, Knoxville, TN, USA) in 63 planes with a 15.5-cm field of view (FOV) in 3D mode. We reconstructed 128 Â 128 pixel images using a Hann filter (cutoff frequency ¼ 0.5 cycles/pixel). The average transverse resolutions at 1 and 10 cm from the center of the FOV, measured in 3D mode and determined using a 18 F line source, were 6.52 and 7.16 mm (full-width at half maximum, FWHM), and the average axial resolutions (FWHM) were 3.72 and 5.64 mm at 0 and 10 cm from the center of the FOV, respectively.
A soft plastic facemask (Scrypton Systems, Annapolis, MD, USA), to minimize head motion, was fitted to each subject after positioning on the scanner gantry. A 3-min 68 Ge transmission scan was performed to verify position of the brain in the FOV, and a 20-min 68 Ge transmission scan was performed for attenuation correction. The subject was removed from the gantry, and performed the CPT while seated. Approximately 5 min later, with the CPT underway, FDG (r5 mCi, r185 MBq) was administered as an intravenous bolus, followed by a 20-ml saline flush. At 30 min after the injection, the CPT was stopped, and the subject was allowed to void before being repositioned in the scanner gantry. Brain images were acquired for 30 min (six 5-min frames), beginning 50 min after FDG injection.
Data analysis
Measures of age and educational level were compared using Student's t-test. Group differences in ethnicity or handedness were assessed using Pearson w 2 analysis. We also compared clinical outcome measures, TSH and thyroid hormone levels, vital signs and body weight before and after treatment with L-T 4 using Student's t-tests. Statistical significance for all analyses was set at a ¼ 0.05 (all tests two-tailed).
As a surrogate index for relative brain metabolism, we used relative activity (decay-corrected raw counts) and made comparisons between groups and between time of assay (pre-and post-treatment for the patient group) using Statistical Parametric Mapping (SPM99). [48] [49] [50] Each PET image (decay-corrected raw counts of radioactivity) was coregistered to the corresponding MRI using Automated Image Registration. 51 The MR images were then used to normalize each subject's PET data spatially by linear and nonlinear transformations, 49 which warped the images into a standard coordinate system developed at the Montreal Neurological Institute (MNI space). Normalized images were then smoothed with an 8-mm (FWHM) isotropic Gaussian kernel. The effects of global activity were removed from consideration by proportional scaling.
In SPM, a parametric statistical model is assumed at each voxel to describe the variability in the data in terms of experimental and confounding effects, and residual variability. In this case, the model provides that for each group of subjects, the activity in each voxel (relative to whole-brain activity) is normally distributed, with homogeneous variance about a group mean. The hypothesis that the group means for each voxel are homogeneous is assessed with Student's t-test, giving an image SPM{t}, where voxel values are t statistics. The multiple comparisons problem of simultaneously assessing all the voxel statistics is addressed by modeling the image as a sample of a continuous Gaussian random field. For each voxel, the corrected P-value is the probability for finding at least one voxel in the search volume with a greater or equal t. For each cluster of contiguous voxels with t greater than a pre-set threshold, the corrected P-value is the probability of finding at least one cluster that is at least that large. For whole-brain SPM exploratory analysis, the multiple comparisons correction is based on all gray matter voxels in the brain using SPM99 segmentation algorithms.
On the basis of previous studies in bipolar depression, we identified seven volumes of interest (VOIs) in each hemisphere where we expected group differences in relative activity before L-T 4 treatment and normalization after treatment in the patient group. These regions were the middle frontal gyrus (selected as representative of DLPFC-Brodmann areas [BAs] 6, 8, 9, 10, 46) and the subgenual and the subgenual cingulate cortex region depicted by Drevets et al 34 (SGCC) (BA 24, 25) where relative activity was expected to be lower in the patient group; 30, 34, 35 and the amygdala, hippocampus, dorsal and ventral striatum, and thalamus, where relative activity was expected to be higher. 34, 36 Activity was also expected to be higher in the midline (right and left combined) cerebellar vermis, 36 The VOIs were drawn on the structural MR template provided in SPM99, using MEDx software (Sensor Systems, Sterling, VA, USA) with reference to the cited papers that argued for including these regions, and aided by use of the Talairach and Tournaux atlas 52 and the Human Brain atlas of Duvernoy. 53 We used the SPM99 small volume correction (SVC) approach to assess each experimental question for each VOI. Within each VOI, the probability of obtaining the largest cluster of affected voxels and the peak voxel height was then corrected for the number of voxels included in the VOI, using the Gaussian Theory of Random Fields. The voxel height threshold for inclusion in clusters was P ¼ 0.05 (uncorrected). VOI was considered to show a significant group difference (or treatment effect) if it contained a cluster with Po0.05 for spatial extent (corrected). In each VOI that showed a significant effect the cluster size and corresponding corrected P value are presented. Also, the coordinates and P-value for the peak voxel (corrected for VOI search volume) are tabled to facilitate comparisons with other studies.
Although our primary approach for each experimental question was an assessment of preselected VOIs, the SVC approach in SPM requires a wholebrain analysis as a preliminary step. Use of the same criteria that we selected for the SVC analyses would be expected to produce fewer statistically significant findings when correcting for many more simultaneous comparisons in the larger whole-brain volume. We present the findings, nonetheless, to allow exploratory analysis of the rest of the brain.
To test our hypotheses, we first generated the whole-brain statistical parametric map to test the difference between groups before treatment. For this analysis, individual subject effects were not modeled to allow assessment of group differences. A separate analysis assessed the interaction of session (1 vs 2) with group (bipolar vs control). A third SPM analysis assessed the degree to which change in relative activity after treatment was correlated with change in clinician-rated depression of bipolar subjects (HRSD 21 ). To interpret these interactions, additional contrasts assessed the activity difference between sessions separately within each group.
Further, we noted which effects maintained statistical significance after applying the Bonferroni correction for 15 regions (seven bilateral regions plus midline cerebellar vermis) and the number of comparisons. Using this approach, the nominal alpha level for a particular region must be less than 0.05 divided by the number of comparisons in order to exhibit a true alpha level of 0.05. This evidentiary criterion is overly conservative however, because it assumes tests of the individual VOIs are independent of one another. This assumption is not likely to be correct.
Results
Treatment outcome
The groups (n ¼ 10 each) did not differ significantly in age, gender, education, ethnicity, and handedness ( Table 1 ). All of the bipolar patients who received the L-T 4 treatment, completed the study, and exhibited declines in depression scores on the clinician and self-reporting rating scales (P'so0.001) ( Table 2) . At the end of the treatment period, seven patients were classified as full responders and three as partial responders.
The mean L-T 4 dose at the end of the study was 320742.1 mg/day (300 mg/day in eight patients, 400 mg/day in two patients (partial responders)). Thyroid hormone levels increased significantly and basal TSH levels decreased significantly with L-T 4 treatment ( Table 2 ). There was no significant correlation between pre-post changes in thyroid hormone levels and pre-post changes in HRSD scores. Systolic blood pressure decreased significantly while heart rate, diastolic blood pressure, and body weight did not change significantly with L-T 4 treatment ( Table 2) . L-T 4 treatment was well tolerated, with no serious adverse events or side effects that warranted discontinuation of treatment.
CPT performance CPT data were collected during both scan sessions for 10 control subjects and nine bipolar patients. Data from one patient were lost due to computer error. Mean accuracy for bipolar patients for the first session was 96.50% and for the second session was 96.06%. For control subjects, mean accuracy for the first session was 93.24% and for the second session was 95.27%. The overall distribution was highly skewed (skew ¼ À3.5770.38). Therefore, accuracy data were normalized using a logarithmic transformation (log (1 þ % errors)). The resulting skew was 0.5770.38. Repeated measures analysis of normalized accuracy 
Group differences in relative glucose metabolism before L-T 4 Treatment
Patients with bipolar disorder exhibited differences in relative regional activity compared with controls at baseline (before L-T 4 treatment for the patients) ( Table  3 , Figure 1 ). In the analysis of preselected volumes of interest, relative activity in the patients was significantly higher in the right subgenual cingulate cortex, left thalamus, right amygdala, right hippocampus, right ventral striatum, and cerebellar vermis; it was lower in the bilateral middle frontal gyri. The relatively higher subcortical activity in the hippocampus, ventral striatum, and cerebellar vermis maintained statistical significance (ie, Po0.003) after Bonferroni correction for number of tests.
The whole-brain analysis, using a voxel height threshold for inclusion in clusters of P ¼ 0.05 (uncorrected), revealed a posterior inferior cluster of 25 188 voxels where patients had higher relative activity than controls (spatial extent cluster Po0.0005 corrected for whole-brain volume). This cluster included most of the cerebellum and extended anteriorly to encompass the right subgenual cingulate cortex, left thalamus, right amygdala, right hippocampus, and right ventral striatum.
There were also two large clusters (both spatial extent Po0.0005) where control subjects had higher relative activity than bipolar patients. These consisted of a superior dorsomedial cluster of 6541 voxels extending from the medial and superior frontal gyri (BA 8) inferiorly to the middle cingulate cortex (BA 32, 24) , that included the right middle frontal gyrus, and a more posterior cortical cluster of 5643 voxels extending from the posterior cingulate (BA 23, 29, 30, 31) posteriorly to the anterior occipital lobe (BA 19).
Relative brain metabolic group differences after L-T 4 treatment
At the time of the second PET assessment, which corresponded to the post-treatment measurement in the bipolar depressed patient group, the patient group no longer showed higher relative activity than the control group in the subgenual cingulate cortex, amygdala, ventral striatum, and thalamus (Table 3) . The relative hyperactivity, compared with control subjects, was still apparent, however, in the right hippocampus (P ¼ 0.002), and the cerebellar vermis (Po0.0005). The whole-brain analysis revealed a cluster of 23 221 voxels that included both of these latter regions.
Further, after treatment, patients still had lower relative activity than control subjects in the middle frontal gyri gyri (P (left) ¼ 0.003, P (right) ¼ 0.053). A frontal cluster of 3623 voxels including the left middle frontal gyrus was significant for the wholebrain analysis.
Treatment-related change in relative brain metabolism
To assess areas where cerebral metabolism was altered by L-T 4 treatment, we examined the interaction of PET session with group. This method removes changes from pre-to post-treatment data related to factors, such as novelty, present in both groups, Table  4 presents changes in relative regional activity from the first to the second PET measurement in the preselected VOIs. Treatment with L-T 4 did not significantly increase relative activity in any of the tested VOIs in the bipolar subjects, but did produce regional decreases in relative activity (Figure 2 ). Significant interactions between group and PET session occurred in the right subgenual cingulate cortex, left thalamus, right amygdala, right hippocampus, right dorsal and ventral striatum, and cerebellar vermis. In all cases, the interaction was due to a significant (Po0.05) decrease in relative activity across sessions in the bipolar group, whereas the control group showed no parallel change. In the right ventral striatum, there was also an increase in the control group (Po0.01). The right ventral striatum also survived the Bonferroni correction for number of tests (Table 4 ). In the whole-brain analysis, bipolar subjects, relative to controls, showed increased post-treatment relative activity in a cluster of 25 188 voxels (spatial extent cluster Po0.0005 corrected for whole-brain volume) extending posteriorly from the right postcentral gyrus (BA 1) through the left middle temporal gyrus (BA 39) to the left middle occipital gyrus (BA 18, 19) . There was a subcortical cluster of 7239 voxels where L-T 4 treatment decreased activity more in the bipolar subjects than controls (Po.0005). This cluster included the right subgenual cingulate cortex, left thalamus, right amygdala, right hippocampus, right dorsal and ventral striatum, brainstem (bilaterally) and cerebellar vermis.
Symptom-related change in relative brain metabolism after L-T 4 treatment HRSD score showed significant positive covariance with relative activity in the left amygdala, left hippocampus, left ventral striatum, and left thalamus. The effect in the left amygdala retained significance after Bonferroni correction for number of comparisons (Table 5, Figure 3 ).
In the whole-brain analysis, HRSD score showed significant positive covariance with a left brain cluster of 4347 voxels extending from the insula inferiorly through the basal ganglia, to include the left amygdala, left hippocampus, left ventral striatum Tables 3-5 , the cluster-level corrected P-value represents the probability, under the null hypothesis, of obtaining any cluster with a spatial extent this large or larger (number of voxels), within the VOI search volume. b In Tables 3-5 , the voxel-level corrected P-value represents the probability, under the null hypothesis, of obtaining any voxel with a Z-score this large or larger, within the VOI search volume. c Significant difference after Bonferroni correction for the number of tests.
and left thalamus (spatial extent cluster Po0.001 corrected for whole-brain volume).
Discussion
This study is the first to use FDG-PET to investigate the effects of supraphysiological doses of L-T 4 on the regional brain metabolism in subjects suffering from bipolar disorder. In the depressed bipolar women studied here, the addition of L-T 4 to an otherwise stable treatment regimen was well tolerated and resulted in a significant decline in depression scores. The findings are consistent with prior animal and human data suggesting that thyroid hormone can modulate regional metabolism in the mature brain. Furthermore, these effects occur in structures integral to affect regulation, and which have been specifically implicated in bipolar disorder. The patterns of brain activity observed during the depressed phase of bipolar disorder, before treatment with L-T 4 , confirm previous findings on patients with bipolar depression. 35, 36 Baxter et al 36 observed lower relative activity in the DLPFC and Ketter et al 36 reported higher relative activity in subcortical regions, including right amygdala, bilateral accumbens, ventral caudate and putamen, as well as bilateral thalamus and cerebellum, compared to healthy control subjects. Similarly, patients in the present study had lower relative activity in the bilateral middle frontal gyri (within DLPFC), and higher relative activity in the left thalamus, right amygdala, right hippocampus, right dorsal and ventral striatum (including accumbens and putamen), and cerebellar vermis. However, whereas Drevets et al 34 reported lower activity in a small area of the subgenual cingulate gyrus in familial bipolar depression, we found the same region had increased activity, as did the subcortical structures. Discrepancies in the results of these two studies may derive from differences in the patient populations studied and the task performed. In the study by Drevets et al, 34 patients did not perform an auditory CPT during the FDG injection and uptake period, but were resting with eyes closed. Also, in contrast to the present study, they were unmedicated and were not selected for refractoriness to antidepressant medications. 34 Compared to the control subjects, patients in this study manifested higher relative activity in the cerebellar vermis than control subjects; and this difference persisted after treatment with L-T 4 , despite clinical improvement. However, other investigators also found higher relative cerebellar activity in bipolar 36 and also unipolar depressed patients who had depression with cognitive impairment compared Figure 1 Brain areas where relative activity differed between the bipolar group and the control group. In this and all subsequent figures, statistical parametric maps were generated using SPM99. Colors superimposed on the gray-scale structural MR template indicate areas where the height threshold for the contrast (whole-brain) was tZ1.69 (P ¼ 0.05). Arrows indicate locations where clusters exhibited Po0.05 for spatial extent (corrected for search volume of the relevant VOI but not the number of regions). Coordinates are in MNI space. As the SPM maps shown here were generated from wholebrain analyses, additional areas not selected a priori for SVC comparisons may also show differences. However, unless they retain statistical significance after whole-brain volume correction, they cannot be constituted as evidence. SGCC ¼ subgenual cingulate cortex.
to those without it. 54 It strengthens these findings that in all analyses whole-brain results supported the results of the VOI measurements.
The fact that all patients and comparison subjects in this study had normal peripheral thyroid function is important in evaluating the shifts in regional brain metabolism that we observed following the administration of high-dose L-T 4 . Early studies investigating the adjunctive use of thyroid hormones in treatmentresistant unipolar and bipolar disease were founded upon the hypothesis that a failing thyroid economy, or subclinical thyroid disease, had compromised neuronal adaptation, thus impairing the therapeutic response to standard pharmacological therapies. 23, 55 Indeed, indices of disturbed peripheral thyroid metabolism are present in many patients with affective disorder, and in the rapid cycling phenotype there is an increased incidence of hypothyroidism.
56
There is also growing evidence that thyroid measures in the low normal range may result in a less than optimal outcome in the acute and long-term treatment of bipolar disorder. 57, 58 Our own studies, however, indicate that many patients who respond to thyroid supplementation do not have peripheral thyroid disease. 8, 10 Such is the case in the sample presented here, where indices of peripheral thyroid function fell within general population norms.
In addition to demonstrating normal peripheral metabolism, most patients with bipolar disorder, who are treated with supraphysiological doses of L-T 4, respond differently to the hormone than do those with pre-existing thyroid disease. The doses of L-T 4 required to achieve therapeutic effect in most studies using adjunctive L-T 4 are higher (200-500 mg/day) than those doses recommended in the treatment of hypothyroidism, which are typically in the range of 100-150 mg/day. 59 The patients tolerate the high doses of L-T 4 surprisingly well, with none of the serious side effects associated with hyperthyroxinemia, such as loss of bone mineral density, even when treated long-term. [60] [61] [62] This low rate of side effects in patients with mood disorders who are receiving supraphysiological doses of L-T 4 contrasts with that typically seen in patients with primary thyroid disease. For example, patients with thyroid carcinoma who are treated with high doses of L-T 4 commonly complain of symptoms similar to thyrotoxicosis. Also, as part of an ongoing effort to define the efficacy and safety parameters of supraphysiological L-T 4 , we found that under well-controlled conditions healthy control subjects and depressed patients respond differently to high-dose L-T 4 . 45 Depressed patients exhibit less elevation in the serum levels of thyroid hormones, and they significantly fewer side effects. 45 How can this conundrum be understood in the context of our findings? A syndrome of peripheral resistance to thyroid hormone in refractory bipolar patients is one possibility. 63 Another hypothesis is that these patients have a ''central'' deficit of the thyroid economy, and that thyroid hormone made available to brain by the hyperthyroxinaemia offsets the deficiency. The observed profound changes in relative cerebral metabolism associated with a rising blood level of thyroid hormone are consistent with such a hypothesis.
While dependent upon peripheral metabolism of thyroid hormone for a stable supply of thyroxine, the brain tightly controls its own thyroid hormone economy through specific deiodination enzymes. 64 In addition, triiodothyronine (T 3 ), the active hormone, acts through nuclear receptors that are widely distributed in the adult rat brain (corresponding human data are not available), with higher densities in the amygdala and hippocampus (which were affected in this study) and lower densities in the brain stem. 13, 65, 66 The T 3 receptors are ligandmodulated transcription factors, and thyroid hormone regulates a number of genes in the brain. 13 These genes encode proteins of myelin, neurotrophins and their receptors, transcription factors, and proteins involved in intracellular signaling pathways. 13, 21 While we are only beginning to understand the regulatory cascade through which the thyroid hormones exert their behavioral effects in humans, the brain's independence of peripheral thyroid metabolism suggests that an understanding of the therapeutic efficacy of high-dose L-T 4 in the malignant bipolar syndromes requires further investigation of the details of this cascade. Particularly relevant is the fact that the thyroid hormone economy in the brain has profound impact upon neurotransmitter systems, particularly those involving serotonin 67 and norepinephrine, 68 which are important in the regulation of affect and behavior. While it is not yet clear whether these monoamine systems include the common pathway through which the behavioral effects of thyroid hormone metabolism are expressed, investigating such questions through brain imaging, employing selective radioligands, is now possible.
It is unclear if the results are generalizable to a male patient sample. Another limitation of this study is the relatively small sample size. With respect to the therapeutic response, the power was adequate because of the robust effect. The fact that seven of 10 patients showed a response to L-T 4 is remarkable but similar to preliminary previous findings in patients during a phase of refractory major depressive episode. 10 However, it is uncertain to what degree changes in brain activity were a direct response to L-T 4 as opposed to a secondary effect of improved mood. Since all of the patients were partial or full responders, it is difficult to dissociate direct effects of L-T 4 on brain metabolism from secondary effects of improvement in mood. For a definite answer, a larger sample would be needed that would include nonresponders as well. On the other hand, in addition to the improvement in mood, L-T 4 treatment accompanied significant decreases in relative activity of all six VOIs that had increased pretreatment metabolism (as well as the dorsal striatum). Another clue may be gleaned from the significant and direct association between post-treatment improvement in mood (reduction of HRSD rating) and the reduction of relative activity in subcortical structures (left thalamus, amygdala, hippocampus, and ventral striatum) (Table 5, Figure 3) .
It is compelling that bipolar patients' mood improvement was accompanied by a decrease in relative metabolism in the limbic structures, reported to be hypermetabolic in bipolar depression, both here and in previous studies. 35, 36 Although we did not formally test laterality effects because of inadequate power, the pretreatment group difference in relative glucose metabolism of limbic regions and post-treatment normalization (toward the control pattern) were lateralized to the right hemisphere (except for the left thalamus and cerebellar vermis). However, in this limited sample, the extent to which mood improved was correlated with the reduction in relative metabolic activity in the left subcortical regions (left thalamus, amygdala, hippocampus and ventral striatum) (Table 5, Figure 3 ). This apparent discrepancy may reflect lateralization of structural parameters in the brains of patients with bipolar disorder, [69] [70] [71] and warrants further study in a larger sample.
Functionally, it is important to note that besides the right-sided changes, bipolar patients produced significant decreases in relative metabolism of left hemisphere hippocampus (P ¼ 0.04; left amygdala P ¼ 0.06) after L-T 4 treatment. These decreases do not appear in Table 4 because there were also small metabolic decreases from the first to second scan in control subjects in the left, but not the right hippocampus, amygdala and ventral striatum (significant at P ¼ 0.04 in the latter), so there were no left-sided differences between the groups. Decreased left-sided metabolism in both groups may be related to reduced novelty and associated emotional states, such as interest or anxiety, during repeated scanning sessions. 72 In addition, the patients studied here were also taking antidepressants and mood stabilizing medications other than L-T 4 , which could influence regional brain function and therapeutic improvements. It seems unlikely, however, that these ongoing heterogeneous medications played a major role in the observed shifts in regional brain activity and mood improvements of the bipolar patients as the medication regimen of each patient was held steady in the 6 weeks prior to the study period. Furthermore, there were no changes in dose during the three weeks before the baseline PET evaluation.
With these caveats, we conclude that levothyroxine may improve mood in patients with resistant bipolar depression by affecting brain metabolism in the prefrontal, subcortical and limbic circuits that have been previously implicated in affective disorders. Our findings suggest that further study with additional controls is warranted. Administration of placebo or other active medication to patients with bipolar disorder and of L-T 4 to euthymic healthy subjects would allow determination of the extent to which changes in brain activity reflect direct response to L-T 4 , and to what extent they are mediated by improved mood.
